KZIA - KAZIA THERAPEUTICS LTD
8.25
-0.260 -3.152%
Share volume: 134,304
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.14%
PREVIOUS CLOSE
CHG
CHG%
$8.51
-0.26
-0.03%
Fundamental analysis
0%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
0%
Performance
5 Days
-6.04%
1 Month
44.23%
3 Months
-47.01%
6 Months
2.48%
1 Year
768.70%
2 Year
3,998.36%
Key data
Stock price
$8.25
DAY RANGE
$7.90 - $8.62
52 WEEK RANGE
$0.60 - $17.40
52 WEEK CHANGE
$768.70
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-29-2025
Company detail
CEO: James S. Garner
Region: US
Website: kaziatherapeutics.com
Employees: 12
IPO year: 1999
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing
Region: US
Website: kaziatherapeutics.com
Employees: 12
IPO year: 1999
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing
Kazia Therapeutics Limited is an oncology-focused biotechnology company. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway. It is also developing EVT801, an investigational new drug for various forms of cancer.
Recent news